Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Multiple System Atrophy companies are Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others.
(Albany, United States) 'Multiple System Atrophy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple System Atrophy Market.
As per DelveInsight's assessment, globally, Multiple System Atrophy pipeline constitutes 20+ key companies continuously working towards developing 22+ Multiple System Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Multiple System Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details
Request for sample report to know in detail about drugs and companies in pipeline @ Multiple System Atrophy Pipeline Outlook
Some of the key takeaways from the Multiple System Atrophy Pipeline Report:
Multiple System Atrophy Companies across the globe are diligently working toward developing novel Multiple System Atrophy treatment therapies with a considerable amount of success over the years.
Multiple System Atrophy companies working in the treatment market are Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others, are developing therapies for the Multiple System Atrophy treatment
Emerging Multiple System Atrophy therapies in the different phases of clinical trials are- NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others are expected to have a significant impact on the Multiple System Atrophy market in the coming years.
are expected to have a significant impact on the Multiple System Atrophy market in the coming years. In May 2025, Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ('Alterity' or 'the Company'), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATH434 for the treatment of Multiple System Atrophy (MSA). This designation is intended to accelerate the development and review of novel investigational products such as ATH434 and recognizes its potential as an innovative approach to address the high unmet need for treating MSA, a disease with no approved therapy.
In February 2025, H. Lundbeck A/S (Lundbeck) today announced that amlenetug has received Fast Track designation from the United States (US) Food and Drug Administration (FDA).
In December 2024, Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology firm focused on creating disease-modifying therapies for neurodegenerative disorders, announced that the final participant in its ATH434-201 Phase 2 trial has completed the study. This randomized, double-blind, placebo-controlled trial targets early-stage multiple system atrophy (MSA). With this milestone reached, topline results are anticipated by late January or early February 2025.
Multiple System Atrophy Overview
Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by Multiple System Atrophy autonomic dysfunction, Multiple System Atrophy parkinsonism, and Multiple System Atrophy cerebellar ataxia. Multiple System Atrophy symptoms often include orthostatic hypotension, urinary incontinence, tremors, bradykinesia, muscle rigidity, gait imbalance, and coordination problems. Multiple System Atrophy diagnosis typically relies on clinical evaluation supported by MRI findings, which may show putaminal or cerebellar atrophy, although no definitive test exists. Multiple System Atrophy pathology reveals glial cytoplasmic inclusions containing alpha-synuclein, distinguishing it from similar disorders.
Multiple System Atrophy progression is usually rapid, leading to severe disability within a few years of onset. Multiple System Atrophy treatment remains symptomatic, aiming to manage blood pressure fluctuations, motor symptoms, and urinary issues. While Multiple System Atrophy levodopa responsiveness is often poor compared to Parkinson's disease, some patients may experience temporary benefit. Multiple System Atrophy prognosis is generally poor, with an average survival of 6 to 10 years post-diagnosis.
Ongoing Multiple System Atrophy research explores neuroprotective agents and disease-modifying therapies. Multiple System Atrophy awareness is essential for early recognition and multidisciplinary care to optimize patient quality of life.
Get a Free Sample PDF Report to know more about Multiple System Atrophy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight
Emerging Multiple System Atrophy Drugs Under Different Phases of Clinical Development Include:
NM-402: Neuramedy Co.,Ltd
Neuramedy Co.,Ltd PMN442: ProMIS Neurosciences
ProMIS Neurosciences ENT-01: Enterin Inc.
Enterin Inc. NC-2500: Nippon Chemiphar
Nippon Chemiphar CS10BR05: CORESTEM, Inc
CORESTEM, Inc AAV2-GDNF: Brain Neurotherapy Bio, Inc.
Brain Neurotherapy Bio, Inc. KM-819: Kainos Medicines
Kainos Medicines ATH434: Alterity Therapeutics
Alterity Therapeutics Lu AF82422: H. Lundbeck A/S
H. Lundbeck A/S Verdiperstat: Biohaven, Ltd
Biohaven, Ltd Ampreloxetine: Selecta Biosciences Inc
Selecta Biosciences Inc ION464: Ionis Pharmaceuticals, Inc
Multiple System Atrophy Route of Administration
Multiple System Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous
Multiple System Atrophy Molecule Type
Multiple System Atrophy Products have been categorized under various Molecule types, such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine
Multiple System Atrophy Pipeline Therapeutics Assessment
Multiple System Atrophy Assessment by Product Type
Multiple System Atrophy By Stage and Product Type
Multiple System Atrophy Assessment by Route of Administration
Multiple System Atrophy By Stage and Route of Administration
Multiple System Atrophy Assessment by Molecule Type
Multiple System Atrophy by Stage and Molecule Type
DelveInsight's Multiple System Atrophy Report covers around 22+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Multiple System Atrophy product details are provided in the report. Download the Multiple System Atrophy pipeline report to learn more about the emerging Multiple System Atrophy therapies
Some of the key companies in the Multiple System Atrophy Therapeutics Market include:
Key companies developing therapies for Multiple System Atrophy are - Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others.
Multiple System Atrophy Pipeline Analysis:
The Multiple System Atrophy pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Multiple System Atrophy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple System Atrophy Treatment.
Multiple System Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Multiple System Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple System Atrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Multiple System Atrophy drugs and therapies
Multiple System Atrophy Pipeline Market Drivers
Increased Awareness and Diagnosis, rising Genetic Research Activities are some of the important factors that are fueling the Multiple System Atrophy Market.
Multiple System Atrophy Pipeline Market Barriers
However, ethical and Practical Challenges in clinical trials, lack of Early and Specific Diagnostic Biomarkers, poor Understanding of Disease Mechanism and other factors are creating obstacles in the Multiple System Atrophy Market growth.
Scope of Multiple System Atrophy Pipeline Drug Insight
Coverage: Global
Key Multiple System Atrophy Companies: Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others
Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others Key Multiple System Atrophy Therapies: NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others
NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others Multiple System Atrophy Therapeutic Assessment: Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies
Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies Multiple System Atrophy Market Dynamics: Multiple System Atrophy market drivers and Multiple System Atrophy market barriers
Request for Sample PDF Report for Multiple System Atrophy Pipeline Assessment and clinical trials
Table of Contents
1. Multiple System Atrophy Report Introduction
2. Multiple System Atrophy Executive Summary
3. Multiple System Atrophy Overview
4. Multiple System Atrophy- Analytical Perspective In-depth Commercial Assessment
5. Multiple System Atrophy Pipeline Therapeutics
6. Multiple System Atrophy Late Stage Products (Phase II/III)
7. Multiple System Atrophy Mid Stage Products (Phase II)
8. Multiple System Atrophy Early Stage Products (Phase I)
9. Multiple System Atrophy Preclinical Stage Products
10. Multiple System Atrophy Therapeutics Assessment
11. Multiple System Atrophy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Multiple System Atrophy Key Companies
14. Multiple System Atrophy Key Products
15. Multiple System Atrophy Unmet Needs
16 . Multiple System Atrophy Market Drivers and Barriers
17. Multiple System Atrophy Future Perspectives and Conclusion
18. Multiple System Atrophy Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name:DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website:https://www.delveinsight.com/consulting
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Billionaire Bill Ackman Has 30% of His Portfolio Invested in 2 Brilliant AI Stocks
Key Points Billionaire Bill Ackman runs Pershing Square Capital Management, a hedge fund that handily beat the S&P 500 over the last five years. Amazon's investments in artificial intelligence should boost profitability in its retail business and drive revenue growth in its cloud business. Uber runs the largest ride-sharing platform in the United States, and that scale makes the company a valuable partner for autonomous driving companies. 10 stocks we like better than Amazon › Bill Ackman's hedge fund, Pershing Square Capital Management, outperformed the S&P 500 (SNPINDEX: ^GSPC) by 7 percentage points in the last year and 19 percentage points in the last five years. That makes Ackman a good source of inspiration. Presently, he has 30% of his portfolio invested in two brilliant artificial intelligence (AI) stocks: 9% is allocated to Amazon (NASDAQ: AMZN) and 21% is allocated to Uber Technologies (NYSE: UBER). Here's why the stocks are compelling investment ideas. Amazon: 9% of Bill Ackman's portfolio Amazon has a strong competitive presence in three markets. It operates the largest online marketplace in North America and Western Europe as measured by gross merchandise sales. It is the third-largest adtech company as measured by revenue. And Amazon Web Services (AWS) is the largest public cloud as measured by infrastructure and platform services spending. Amazon is leaning on artificial intelligence across its retail business to improve customer service, product listings, supply chain management, and developer productivity. Brian Nowak at Morgan Stanley says Amazon's retail business could be the most underappreciated generative AI beneficiary in the technology space, and he estimates cost savings initiatives could raise its operating margin by several percentage points. Meanwhile, AWS is ideally positioned to monetize AI simply because it is the largest public cloud. It accounted for 30% of infrastructure and platform services spending in the recent quarter, while the next closest cloud platform was Microsoft Azure with 20% market share. AWS has also designed custom chips for AI training and inference, and added tools that let developers build generative AI applications and agents. Importantly, Amazon is positioning itself to monetize AI beyond its core e-commerce and cloud businesses. Its subsidiary Zoox builds robotaxis, and the company will launch its first autonomous ride-hailing service in Las Vegas in 2025, followed by other cities in subsequent years. Morgan Stanley estimates Zoox could have commercial robotaxi services in seven U.S. cities by 2028. Looking ahead, Wall Street expects Amazon's earnings to grow at 18% annually over the next three years. That makes the current valuation of 35 times earnings look reasonable, especially when the company beat the consensus earnings estimate by an average of 22% in the last six quarters. Patient investors should take a cue from Bill Ackman and buy a few shares of this stock today. Uber Technologies: 21% of Bill Ackman's portfolio Uber leads the U.S. ride-sharing market with 76% share, according to Bloomberg. It also ranks second in the restaurant food delivery market with 24% share. That scale affords the company a competitive advantage in that it creates a significant amount of data that lets Uber predict demand, route drivers, and set prices more efficiently over time. Uber has another important advantage in its ability to offer ride-sharing and food delivery services through a single mobile app. That makes customer acquisition very cost-efficient because the company can cross-sell users on both sides of its platform. For instance, 31% of first delivery trips come from mobility users, and 22% of first mobility trips come from delivery users. CEO Dara Khosrowshahi recently told analysts that autonomous vehicle (AV) technology will be a $1 trillion opportunity for ride-sharing platforms. Uber is uniquely positioned to benefit given its unparalleled scale. "Uber can deliver the lowest operational costs for our AV partners because we are leaps and bounds ahead on every aspect of go-to-market capabilities," Khosrowshahi said. Indeed, Uber may not be a traditional AI stock, but it could be a major winner as robotaxis become more prevalent due to the many partnerships it has formed with AV companies, according to Mark Mahaney at Evercore. Most notably, Uber connects riders with Waymo robotaxis in Phoenix, Austin, and Atlanta. And it connects riders with WeRide robotaxis in Abu Dhabi and Dubai, with 15 additional cities to follow in the next five years. Wall Street estimates Uber's earnings will increase at 26% annually over the next three years, a reasonable estimate given the ride-sharing market is forecast to expand at 21% annually through 2033, according to Straits Research. That makes the current valuation of 16 times earnings look relatively cheap. Long-term investors should feel confident buying a small position in this stock today. Should you invest $1,000 in Amazon right now? Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* Now, it's worth noting Stock Advisor's total average return is 1,071% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Trevor Jennewine has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Microsoft, and Uber Technologies. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
National Post
3 hours ago
- National Post
Air Canada-CUPE Negotiations End in Impasse
TORONTO — Negotiations between CUPE and Air Canada have ended in impasse. Article content Air Canada still refuses to compensate flight attendants for all hours worked. Article content The union has been firm: all safety-related duties should be paid at full hourly rate. Air Canada does not agree. Article content On wages, Air Canada's last offer will still leave flight attendants living below poverty levels for many years to come. Article content We are heartbroken for our passengers. We do not want to go on strike, and we do not want to be locked out, but it is clear that Air Canada has no incentive to bargain. Article content Rather, Air Canada has refused to bargain in good faith due to the likelihood of the federal government using Section 107 of the Canada Labour Code to interfere in negotiations and have a contract imposed by an outside third-party arbitrator. Article content Article content Article content Article content Article content Contacts Article content Hugh Pouliot CUPE Media Relations (EN) hpouliot@ 613-818-0067 Article content Article content
CTV News
4 hours ago
- CTV News
CTV National News: Battle over wages continues as strike officially begins
Watch Kamil Karamali has the latest on where negotiations between Air Canada and the union representing its flight attendants stand.
